Quick Takeaways
- PERCEPTIVE ADVISORS LLC filed SCHEDULE 13G/A for INHIBIKASE THERAPEUTICS, INC. Common Stock, $0.001 par value (IKT).
- Disclosed ownership: 10%.
- Date of event: 31 Dec 2025.
PERCEPTIVE ADVISORS LLC - 31 Dec 2025 SCHEDULE 13G/A Report for INHIBIKASE THERAPEUTICS, INC. Common Stock, $0.001 par value (IKT)
- Filing Manager
- PERCEPTIVE ADVISORS LLC
- Reporting Manager
- Perceptive Advisors LLC
- Symbol
- IKT
- Shares outstanding
- 128,294,725 shares
- Disclosed Ownership
- 12,816,643 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 16:00:03 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"PERCEPTIVE ADVISORS LLC disclosed 10% ownership in INHIBIKASE THERAPEUTICS, INC. Common Stock, $0.001 par value (IKT) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Feb 2026, 16:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Perceptive Advisors LLC | 10% | 12,816,643 | 0 | 12,816,643 | /s/ Joseph Edelman | Joseph Edelman, Managing Member | |
| Joseph Edelman | 10% | 12,816,643 | 0 | 12,816,643 | /s/ Joseph Edelman | Joseph Edelman | |
| Perceptive Life Sciences Master Fund, Ltd. | 10% | 12,816,643 | 0 | 12,816,643 | /s/ Joseph Edelman | Joseph Edelman, Managing Member |